While the Human Genome Project was declared complete 20 years ago, the mapping of the human genome was not truly complete. As the author of… Read More »Filling In The Missing Parts Of The Genetic Map Could Translate Into Huge Gains For This Biotech
When it comes to the three biotech stocks featured in today’s article, all of which have experienced recent struggles, the author notes that their management… Read More »These 3 Struggling Biotechs Could Experience Spring Bumps
In the genome sequencing space, the stock highlighted in today’s article may not be the best stock – yet. As the author details, however, “when… Read More »This Genome Sequencing Stock’s Monster Run May Be Far From Over
Of the two ways companies can return cash to shareholders – dividends and share buybacks – which is better for investors? How about a combination… Read More »Expand Your Understanding Of ‘Yield’ And Widen Your Opportunity Set
While everything appears to be falling into place for the North American marijuana industry to be an unprecedented growth opportunity, today’s article notes that, when… Read More »These Pot Stocks Have Gone From Promising And Popular To Problem-Plagued In A Matter Of Months
For mature companies without significant growth opportunities to fund, and with shareholders to please, there are two standard ways to use excess cash: distribute said… Read More »Are Dividends Or Share Buybacks Better For Investors?
The sentiment currently surrounding gold – the price of which has fallen 6% this year – can be described as “maximum pessimism,” notes the author… Read More »Why To Own Gold – And A Fund To Really Own Gold
“One way to get capital gains from REITs is to focus on buying those real estate investment trusts that will increase the dividends paid to… Read More »Get Ahead Of These November REIT Dividend Hikes
Companies that want to deploy extra cash in a way that benefits shareholders quickly can pay dividends or buy back shares – and, as the… Read More »These Undervalued Companies Are Big On Rewarding Shareholders
The Jackson Square SMID-Cap Growth Fund has consistently beaten its peers – and today’s article outlines the fund’s selection process (“The co-managers don’t buy the… Read More »“Growth Plus” Stock Picks From This Peer-Beating Fund